March 2025 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.
June 2025 in “Journal of Education Health and Sport” Oral JAK inhibitors show promise for treating alopecia areata but have challenges like relapse and side effects.
8 citations
,
May 2017 in “IUBMB life” Astrotactin proteins are important for brain and skin development and are linked to several neurodevelopmental disorders.
June 2025 in “British Journal of Dermatology” Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
August 2024 in “JAAD Case Reports” Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.
20 citations
,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
November 2024 in “Skin Appendage Disorders” Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.
September 2023 in “Drugs in context” Baricitinib is a promising treatment for alopecia areata.
2 citations
,
November 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib effectively regrows hair in adults with alopecia areata and is well tolerated.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
November 2005 in “The Journal of Urology”
April 2025 in “Vestnik dermatologii i venerologii” JAK inhibitors like tofacitinib are effective and safer for severe alopecia areata than glucocorticosteroids.
36 citations
,
November 2005 in “Journal of The American Academy of Dermatology” Topical latanoprost doesn't effectively regrow hair in severe eyebrow alopecia areata cases.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
May 2024 in “Drugs & Therapy Perspectives” New treatments like JAK inhibitors offer hope for better alopecia areata management.
October 2025 in “Figshare” Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.
October 2004 in “Australian Prescriber” Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.
January 2026 in “Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
May 2014 in “Japanese Society of Anti-Aging Medicine”
March 2025 in “Meditsinskiy sovet = Medical Council” Dupilumab and oral JAK inhibitors are effective for treating alopecia areata with atopic diseases.
September 2023 in “Journal of The American Academy of Dermatology” Baricitinib treatment can help regrow scalp hair and eyebrows or eyelashes in people with severe alopecia areata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.
1 citations
,
September 2022 in “Nepal journal of dermatology, venereology & leprology” Apremilast shows promise for several skin conditions but needs more research.
77 citations
,
June 2017 in “Advances in Therapy” New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
14 citations
,
April 2023 in “Acta Dermato Venereologica” Upadacitinib effectively treated severe hair loss in a child.
1 citations
,
January 2023 in “Przegląd Dermatologiczny” The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.
20 citations
,
November 2017 in “JAAD case reports” Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.
November 2022 in “Journal of Investigative Dermatology” Statins may help treat alopecia areata by reducing harmful immune interactions.